DOCSLIB.ORG

Neuroscience, Society and Policy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuroscience, Society and Policy The Royal Society For further information society and policy Module 1: Neuroscience, Waves Brain Society Royal The January 2011 Centre Report 01/11 Science Policy The Royal Society is a Fellowship of more than 1400 outstanding The Royal Society individuals from all areas of science, mathematics, engineering and Science Policy Centre medicine, who form a global scientifi c network of the highest 6–9 Carlton House Terrace calibre. The Fellowship is supported by over 140 permanent staff London SW1Y 5AG with responsibility for the day-to-day management of the Society T +44 (0)20 7451 2500 and its activities. The Society encourages public debate on key F +44 (0)20 7451 2692 issues involving science, engineering and medicine, and the use of E [email protected] high quality scientifi c advice in policy-making. We are committed to W royalsociety.org delivering the best independent expert advice, drawing upon the experience of the Society’s Fellows and Foreign Members, the wider scientifi c community and relevant stakeholders. We are working to achieve fi ve strategic priorities: • Invest in future scientifi c leaders and in innovation • Infl uence policymaking with the best scientifi c advice • Invigorate science and mathematics education • Increase access to the best science internationally • Inspire an interest in the joy, wonder and excitement of scientifi c discovery Brain Waves Module 1: Neuroscience, society ISBN 978-0-85403-879-4 and policy ISBN: 978-0-85403-879-4 Issued: January 2011 Report 01/11 DES2015 January 2011 Founded in 1660, the Royal Society is the independent scientific academy of the UK, dedicated to promoting excellence in science 9 780854 038794 Registered Charity No 207043 Price £20 Cover image: The cover image is a drawing of Purkinje cells (A) and granule cells (B) from pigeon cerebellum by Santiago Ramón y Cajal, 1899. Instituto Santiago Ramón y Cajal, Madrid, Spain. Brain Waves Module 1: Neuroscience, society and policy RS Policy document 01/11 Issued: January 2011 DES2015 ISBN: 978-0-85403-879-4 © The Royal Society, 2011 Requests to reproduce all or part of this document should be submitted to: The Royal Society Science Policy Centre 6–9 Carlton House Terrace London SW1Y 5AG Tel +44 (0)20 7451 2500 Email [email protected] Web royalsociety.org Brain Waves Module 1: Neuroscience, society and policy Contents 1 Introduction and summary 1 The Brain Waves Project 1 Summary 1 Acknowledgements 2 2 Contemporary neuroscience and technology 5 2.1 The scope and limits of neuroimaging 7 Background 7 Neuroimaging techniques 7 Uses of neuroimaging 11 Limits of neuroimaging 13 Policy questions and issues 16 Conclusion 17 References and further reading 18 Box 1: Neuroimaging and lie detection 18 2.2 Neuropsychopharmacology 19 Background 19 New developments in neuropsychopharmacology 19 Varied drug effects in the brain 20 Conclusion 26 The Royal Society Brain Waves Module 1 I January 2011 I iii References and further reading 27 Box 2: Cognitive enhancing drugs 28 2.3 Neural interfaces and brain interference 31 Background 31 Early studies that provided the impetus for NIS developments 32 The current state of the science 32 Potential clinical applications 33 NISs as tools for neuroscience research 34 Recurrent NIS and ‘cognitive prostheses’ 35 Technical challenges and opportunities 35 Less / non-invasive NISs and extrapolation to the games and toy industry 36 Conclusion 37 References and further reading 37 Box 3: Neural interface systems 38 Box 4: Transcranial magnetic stimulation 39 2.4 A determinist view of brain, mind and consciousness 41 Background 41 Implicit assumptions 41 The evidence 42 Conscious versus unconscious processing 42 Wrong intuitions 43 Differences between unconscious and conscious decisions 44 Why is intuition in confl ict with neurobiological evidence? 45 Potential consequences for our legal systems 45 Punishment and confi nement 46 iv I January 2011 I Brain Waves Module 1 The Royal Society Attenuating conditions 46 References and further reading 47 Box 5: The biological becomes personal: philosophical problems in neuroscience 49 2.5 Reward, decision-making and neuroeconomics 51 Background 51 Aims of neuroeconomics: perspective of neuroscience 51 Aims of neuroeconomics: perspective of economics 52 Current state of neuroeconomic research: how the factors that infl uence decisions are represented in the brain 53 Current state of neuroeconomic research: how one possible action is selected from multiple options 54 Current state of neuroeconomic research: social decisions 54 Policy questions 56 Neuromarketing 57 References and further reading 57 3 Neuroscience and society 59 3.1 Benefi ts and opportunities 61 Background 61 Application to policy 61 Opportunities 64 Challenges and solutions 65 Conclusion 66 References and further reading 66 3.2 Risks 69 Background 69 Is increased knowledge of the brain itself hazardous? 69 The Royal Society Brain Waves Module 1 I January 2011 I v Policy issues 70 Drugs for social control? 71 The military and neurotechnoscience 75 Conclusion 76 References and further reading 76 3.3 Neuroethics 77 Background 77 Neuroimaging 78 Genetic neuroscience 79 New medical applications 79 Harmful uses 80 Neuro-enhancement 81 Machine minds? 83 Policy concerns in neuroethics 84 References and further reading 85 3.4 Governance of neuroscience: challenges and responses 87 Three lessons 87 Seven syndromes 90 Three principles 93 References and further reading 96 vi I January 2011 I Brain Waves Module 1 The Royal Society 1 Introduction and summary The Brain Waves project • Module 2: Neuroscience: implications Developments in neuroscience, the study for education and lifelong learning; of the brain and nervous system, are • Module 3: Neuroscience, confl ict and likely to provide signifi cant benefi ts for security; society. Increasing understanding of the brain and advances in technologies to • Module 4: Neuroscience, responsibility study it will enable improved treatment of and the law. neurodegenerative diseases, such as Parkinson’s and Alzheimer’s, and mental illnesses, including depression and Summary schizophrenia. They will increase our This Module 1 report is a collection of insights into normal human behaviour essays that together provide a primer of and mental wellbeing, as well as enabling current developments in neuroscience and other enhancement, manipulation, and highlight interesting issues and questions even degradation of brain function and for society and policy. It is not intended as cognition. an exhaustive review of the science, nor to make specifi c policy recommendations. Neuroscience and neurotechnology Rather, it raises key issues and questions, reach far and wide into disparate fi elds. many of which will be explored in more The array of ‘neuro’ disciplines lend depth in subsequent modules. themselves to applications in diverse areas of public policy such as health, education, In Section 2 of the report we review the law, and security. More broadly, progress state of development of neuroscience in neuroscience is going to raise questions and neurotechnology, discuss the about personality, identity, responsibility, translation of this knowledge into useful and liberty, as well as associated social applications or inferences, and raise some and ethical issues. The aim of the Royal of the implications. Section 2.1 explores Society’s Brain Waves project is to explore neuroimaging. Here, we describe some what neuroscience can offer, what are its of the existing tools used to study the limitations, and what are the potential brain, their limitations, and associated benefi ts and the risks posed by particular issues for healthcare, business, applications. criminal justice, and privacy. In Section 2.2 we address developments in neuropsy- This report is the fi rst in a series of four chopharmacology, their application for ‘modules’. Three subsequent modules mental health medicines, wider issues of will consider specifi c policy issues in recreational use, as well as emerging more detail: applications for cognitive enhancement. • Module 1: Neuroscience, society and Neural interfaces and brain interference policy; are the subject of Section 2.3, which The Royal Society Brain Waves Module 1 I January 2011 I 1 reviews those providing direct input to issues such as personal identity, physical the brain to modulate activity and those and moral enhancement, responsibility, that use outputs of brain activity to and artifi cial intelligence. Finally, in Section control external devices or prostheses. 3.4 we draw lessons from the wider Applications in diverse areas of health- governance of science and technology, care and the games industry are dis- suggesting approaches to marshalling cussed. Sections 2.4 and 2.5 address neuroscience in order to maximise the what new developments in neuroscience benefi ts and minimise any risks. may mean for our understanding of Professor Colin Blakemore FRS, Chair, behaviour and decision-making. Section Steering Group, Brain Waves project 2.4 argues that understanding of con- scious and unconscious decision-making processes presents a challenge to our concepts of responsibility and free will. Acknowledgements Section 2.5 explores how recent work in The Brain Waves project is overseen by a behavioural neuroscience is leading to Steering Group, chaired by Professor Colin insights about the neurobiological basis Blakemore FRS. These experts also serve of economic decision-making. as members of three broader Working Groups for Modules 2, 3, and 4. The Royal In Section 3 we examine some of the Society would like to thank all members of opportunities and risks these scientifi c the Steering Group, most of whom have developments present, as well as the authored essays for this volume and all of ethical questions they raise, and whom have overseen its development governance issues that need to be and editing: considered. Section 3.1 describes some of the benefi ts and opportunities in • Professor Colin Blakemore FRS (Chair), neuroscience, with a particular focus on Professor of Neuroscience, University new drugs to combat mental illness and of Oxford; cognitive decline, and the associated role of the private sector.
Load more

Recommended publications
  • E30 SEM. O.C. Disclosed Is a Compound Represented by the Formula (1) (51) Int
    USOO9453000B2 (12) United States Patent (10) Patent No.: US 9.453,000 B2 Kimura et al. (45) Date of Patent: *Sep. 27, 2016 (54) POLYCYCLIC COMPOUND (56) References Cited (75) Inventors: Teiji Kimura, Tsukuba (JP); Noritaka U.S. PATENT DOCUMENTS Kitazawa, Tsukuba (JP); Toshihiko 3,470,167 A 9, 1969 Sarkar Kaneko, Tsukuba (JP); Nobuaki Sato, 3,989,816 A 1 1/1976 Rajadhyaksha Tsukuba (JP); Koki Kawano, Tsukuba 4,910,200 A 3, 1990 Curtze et al. (JP): Koichi Ito, Tsukuba (JP); 5,281,626 A 1/1994 Oinuma et al. M s Tak ishi Tsukub JP 5,563,162 A 10, 1996 Oku et al. amoru Takaishi Tsukuba (JP); 5,804,577 A 9, 1998 Hebeisen et al. Takeo Sasaki, Tsukuba (JP); Yu 5,985,856 A 11/1999 Stella et al. Yoshida, Tsukuba (JP); Toshiyuki 6,235,728 B1 5, 2001 Golik et al. Uemura, Tsukuba (JP); Takashi Doko, g R 1939. E. al. Its SE E. Shinmyo, 7,138.414 B2 11/2006 Schoenafingereatch et al. et al. sukuba (JP); Daiju Hasegawa, 7,300,936 B2 11/2007 Parker et al. Tsukuba (JP); Takehiko Miyagawa, 7,314,940 B2 1/2008 Graczyk et al. Hatfield (GB); Hiroaki Hagiwara, 7,618,960 B2 11/2009 Kimura et al. Tsukuba (JP) 7,667,041 B2 2/2010 Kimura et al. 7,687,640 B2 3/2010 Kimura et al. 7,713,993 B2 5/2010 Kimura et al. (73) Assignee: EISAI R&D MANAGEMENT CO., 7,737,141 B2 6/2010 Kimura et al. LTD., Tokyo (JP) 7,880,009 B2 2/2011 Kimura et al.
    [Show full text]
  • The Use of Non-Human Primates in Research in Primates Non-Human of Use The
    The use of non-human primates in research The use of non-human primates in research A working group report chaired by Sir David Weatherall FRS FMedSci Report sponsored by: Academy of Medical Sciences Medical Research Council The Royal Society Wellcome Trust 10 Carlton House Terrace 20 Park Crescent 6-9 Carlton House Terrace 215 Euston Road London, SW1Y 5AH London, W1B 1AL London, SW1Y 5AG London, NW1 2BE December 2006 December Tel: +44(0)20 7969 5288 Tel: +44(0)20 7636 5422 Tel: +44(0)20 7451 2590 Tel: +44(0)20 7611 8888 Fax: +44(0)20 7969 5298 Fax: +44(0)20 7436 6179 Fax: +44(0)20 7451 2692 Fax: +44(0)20 7611 8545 Email: E-mail: E-mail: E-mail: [email protected] [email protected] [email protected] [email protected] Web: www.acmedsci.ac.uk Web: www.mrc.ac.uk Web: www.royalsoc.ac.uk Web: www.wellcome.ac.uk December 2006 The use of non-human primates in research A working group report chaired by Sir David Weatheall FRS FMedSci December 2006 Sponsors’ statement The use of non-human primates continues to be one the most contentious areas of biological and medical research. The publication of this independent report into the scientific basis for the past, current and future role of non-human primates in research is both a necessary and timely contribution to the debate. We emphasise that members of the working group have worked independently of the four sponsoring organisations. Our organisations did not provide input into the report’s content, conclusions or recommendations.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • AI Watch Artificial Intelligence in Medicine and Healthcare: Applications, Availability and Societal Impact
    JRC SCIENCE FOR POLICY REPORT AI Watch Artificial Intelligence in Medicine and Healthcare: applications, availability and societal impact EUR 30197 EN This publication is a Science for Policy report by the Joint Research Centre (JRC), the European Commission’s science and knowledge service. It aims to provide evidence-based scientific support to the European policymaking process. The scientific output expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. The designations employed and the presentation of material on the maps do not imply the expression of any opinion whatsoever on the part of the European Union concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Contact information Email: [email protected] EU Science Hub https://ec.europa.eu/jrc JRC120214 EUR 30197 EN PDF ISBN 978-92-76-18454-6 ISSN 1831-9424 doi:10.2760/047666 Luxembourg: Publications Office of the European Union, 2020. © European Union, 2020 The reuse policy of the European Commission is implemented by the Commission Decision 2011/833/EU of 12 December 2011 on the reuse of Commission documents (OJ L 330, 14.12.2011, p. 39). Except otherwise noted, the reuse of this document is authorised under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence (https://creativecommons.org/licenses/by/4.0/).
    [Show full text]
  • Cognitive Enhancement and the Emergence of Personhood
    http://dx.doi.org/10.5007/1677-2954.2021.e80030 FROM THE NECESSITY OF BEING HUMAN TO THE POSSIBILITY OF PURSUING A GOOD LIFE: COGNITIVE ENHANCEMENT AND THE EMERGENCE OF PERSONHOOD GIOVANA LOPES1 (UNIVERSITÀ DI BOLOGNA/Italia) BRUNELLO STANCIOLI2 (UFMG/Brasil) ABSTRACT Throughout human history, cognition enhancement has not only been a constant, but also imperative for our species evolution and well-being. However, philosophical assumptions that enhancing cognition by biomedical means goes against some immutable human nature, combined with the lack of conclusive data about its use on healthy individuals and long-term effects, can sometimes result in prohibitive approaches. In this context, the authors seek to demonstrate that cognition enhancement, whether by “natural” or biotechnological means, is essential to the emergence of personhood, and to existence of an autonomous life that is guided by a person’s own conception of the good. In order to do so, the main possibilities of enhancing cognition through biotechnologies, along with its benefits and potentialities, as well as its risks and limitations, will be presented. Following Savulescu and Sandberg’s account on cognitive enhancement, it will be argued that it constitutes both a consumption good, being desirable and happiness-promoting to have well-functioning cognition, and a capital good that reduces risks, increases earning capacity, and forms a key part of human capital. Finally, having in mind that progress in the field of biotechnology aimed at cognition enhancement may improve a person’s (and society’s) well-being, the authors will argue that further research in the field is necessary, especially studies that takes into consideration dimensions such as dose, individual characteristics and task characteristics.
    [Show full text]
  • What Are You?
    Human Being or Human Brain? Animalism and the Problem of Thinking Brains Ida Anderalm Master’s Thesis in Philosophy, 30 credits Spring 2016 Supervisor: Pär Sundström Department of Historical, Philosophical and Religious Studies Abstract Animalismens huvudargument säger att du är det tänkande objektet som sitter i din stol, och enligt animalisterna själva innebär detta att du är identisk med ett mänskligt djur. Argumentet är dock problematiskt då det inte tycks utesluta eventuella tänkande delar hos det mänskliga djuret, som till exempel dess hjärna. Detta beror på att hjärnor också kan beskrivas som tänkande, samt att även de befinner sig inom det spatiella område som upptas av det mänskliga djuret. I den här uppsatsen argumenterar jag för att tänkande hjärnor är ett problem för animalismen och att tesen att vi är identiska med hjärnor är ett verkligt hot mot den animalistiska teorin om personlig identitet. Olika argument som lagts fram mot tesen att vi är hjärnor avhandlas, som till exempel att hjärnor inte existerar och att hjärnor inte tänker. Jag diskuterar även två argument som tidigare använts för att visa att vi är personer snarare än mänskliga djur (the Transplant Intuition och the Remnant Person Problem), men i det här sammanhanget bedöms de utifrån deras förmåga att stödja hjärnteorin. Contents 1. Introduction ............................................................................................................................ 1 1.1 Personal Identity ..............................................................................................................
    [Show full text]
  • TREVOR W. ROBBINS, CBE FRS Fmedsci Fbpss
    TREVOR W. ROBBINS, CBE FRS FMedSci FBPsS Professor of Cognitive Neuroscience and Experimental Psychology Trevor Robbins is accepting applications for PhD students. Email: [email protected] Office Phone: +44 (0)1223 (3)33551 Websites: • http://www.neuroscience.cam.ac.uk/directory/profile.php?Trevor Download as vCard Biography: Trevor Robbins was appointed in 1997 as the Professor of Cognitive Neuroscience at the University of Cambridge. He was elected to the Chair of Experimental Psychology (and Head of Department) at Cambridge from October 2002. He is also Director of the Behavioural and Clinical Neuroscience Institute (BCNI), jointly funded by the Medical Research Council and the Wellcome Trust. The mission of the BCNI is to inter-relate basic and clinical research in psychiatry and neurology for such conditions as Parkinson's, Huntington's, and Alzheimer's diseases, frontal lobe injury, schizophrenia, depression, drug addiction and developmental syndromes such as attention deficit/hyperactivity disorder. Trevor is a Fellow of the British Psychological Society (1990), the Academy of Medical Sciences (2000) and the Royal Society (2005). He has been President of the European Behavioural Pharmacology Society (1992-1994) and he won that Society's inaugural Distinguished Scientist Award in 2001. He was also President of the British Association of Psychopharmacology from 1996 to 1997. He has edited the journal Psychopharmacology since 1980 and joined the editorial board of Science in January 2003. He has been a member of the Medical Research Council (UK) and chaired the Neuroscience and Mental Health Board from 1995 until 1999. He has been included on a list of the 100 most cited neuroscientists by ISI, has published over 600 full papers in scientific journals and has co-edited seven books (Psychology for Medicine: The Prefrontal Cortex; Executive and Cognitive Function: Disorders of Brain and Mind 2:Drugs and the Future: The Neurobiology of Addiction; New Vistas.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • College Annual Report and Accounts 2013-2014
    DOWNING COLLEGE CAMBRIDGE ANNUAL REPORT AND ACCOUNTS for the financial year ending 30 June 2014 The West Range ©Tim Rawle www.dow.cam.ac.uk 2 Contents 5. Financial Highlights 6. Members of the Governing Body 9. Officers and Principal Professional Advisors 11. Report of the Governing Body 67. Financial Statements 77. Principal Accounting Statements 78. Consolidated Income & Expenditure Account 79. Consolidated Statement of Total Recognised Gains and Losses 80. Consolidated Balance Sheet 82. Consolidated Cashflow Statement 85. Notes to the Accounts 3 4 Financial HIGHlIGHtS 2014 2013 2012 £ £ £ Highlights Income Income 10,155,889 9,663,733 9,239,544 Donations and Benefactions Received 5,292,916 3,124,484 2,304,365 Financial | Conference Services Income 2,042,832 2,130,085 1,875,620 Operating Surplus/(Deficit) 320,009 336,783 306,969 2014 Cost of Space (£ per m2) £150.87 £150.20 £156.65 College Fees: June Publicly Funded Undergraduates £4,068/£4,500 £3,951/£4,500 £3,951 30 Privately Funded Undergraduates £7,350 £6,999 £6,000 Graduates £2,424 £2,349 £2,289 Ended loss on College Fee per Student £2,436 £2,630 £1,995 Year Capital Expenditure Investment in Historical Buildings 1,751,811 573,388 446,851 Investment in Student Accommodation 1,499,507 740,562 2,784,000 Assets Free Reserves 8,349,966 13,372,300 11,499,498 Investment Portfolio 35,775,344 34,917,793 31,785,279 Spending Rule Amount 1,617,819 1,543,197 1,505,631 total Return 7.6% 9.2% 6.2% total Return: 3 year average 7.7% 10.3% 10.6% Return on Property 5.8% 7.6% 11.4% Return on Property:
    [Show full text]
  • Human Functional Brain Imaging 1990–2009
    Portfolio Review Human Functional Brain Imaging 1990–2009 September 2011 Acknowledgements The Wellcome Trust would like to thank the many people who generously gave up their time to participate in this review. The project was led by Claire Vaughan and Liz Allen. Key input and support was provided by Lynsey Bilsland, Richard Morris, John Williams, Shewly Choudhury, Kathryn Adcock, David Lynn, Kevin Dolby, Beth Thompson, Anna Wade, Suzi Morris, Annie Sanderson, and Jo Scott; and Lois Reynolds and Tilli Tansey (Wellcome Trust Expert Group). The views expressed in this report are those of the Wellcome Trust project team, drawing on the evidence compiled during the review. We are indebted to the independent Expert Group and our industry experts, who were pivotal in providing the assessments of the Trust’s role in supporting human functional brain imaging and have informed ‘our’ speculations for the future. Finally, we would like to thank Professor Randy Buckner, Professor Ray Dolan and Dr Anne-Marie Engel, who provided valuable input to the development of the timelines and report. The2 | Portfolio Wellcome Review: Trust Human is a Functional charity registeredBrain Imaging in England and Wales, no. 210183. Contents Acknowledgements 2 Key abbreviations used in the report 4 Overview and key findings 4 Landmarks in human functional brain imaging 10 1. Introduction and background 12 2 Human functional brain imaging today: the global research landscape 14 2.1 The global scene 14 2.2 The UK 15 2.3 Europe 17 2.4 Industry 17 2.5 Human brain imaging
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Transplantation and Stem Cell Research in Neurosciences: Where Does India Stand?
    Review Article Transplantation and stem cell research in neurosciences: Where does India stand? Prakash N. Tandon Emeritus Professor, Neurosurgery, All India Institute of Medical Sciences, New Delhi and President, National Brain Research Centre, Manesar, Haryana, India Abstract The nearly absent ability of the neurons to regenerate or multiply has prompted neuroscientists to search for the mean to replace damaged or dead cells. The failed attempts using adult tissue, initiated nearly a century ago, ultimately brought rays of hope when developing fetal neurons were used for transplantation in 1970s. The Address for correspondence: initial excitement was tempered by limited success and ethical issues. But these efforts Dr. Prakash N. Tandon, unequivocally established the feasibility of successful neural transplantation provided National Brain Research Centre appropriate tissue was available. The ability to derive embryonic stem cells with (NBRC), Nainwal More, their totipotent potential by Thomson in 1998 rekindled the interest in their use for Manesar - 122 050, Haryana, India. replacement therapy for damaged brain tissue. The present review surveys the current E-mail: [email protected] status of this promising field of stem cell research especially in respect to their therapeutic potentials for purposes of neural transplantation. A brief account is provided of the ongoing Indian efforts in this direction. PMID: *** DOI: 10.4103/0028-3886.59464 Key words: Adult neural stem cells, embryonic stem cells, neural transplantation Historical Background that for once the neurosurgeons jumped straight from the “rat-to-man” without even waiting for the results of the While attempts at neural transplantation for repair of studies in higher primates.
    [Show full text]